We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Residual impurities encompass the full spectrum of process-related contaminants introduced during upstream cell culture, downstream purification, and final formulation of biopharmaceuticals. These include microbial and fungal contaminants, mycoplasma, endotoxins, host cell proteins (HCP), host cell DNA (HCD), and adventitious viral agents. Even at trace levels, these impurities can compromise cell viability, induce immunogenicity, or pose tumorigenic and infectious risks to patients. Under FDA, EMA, ICH, USP, and NMPA guidelines, sponsors must demonstrate rigorous control and validated detection of process-related impurities from early development through commercial release. At Profacgen, our Residual Impurity Testing platform delivers integrated, phase-appropriate analytical solutions combining classical microbiology, advanced electrophoresis, and quantitative PCR to ensure your biological products meet all safety and quality specifications.
What Challenges Do We Solve?
Profacgen provides impurity testing services for the pharmaceutical industry to help ensure the quality and safety of pharmaceutical products, especially when accuracy and efficiency are critical. We provide comprehensive pharmacopoeial analysis to detect mycoplasma and bacterial contaminants, as well as in vivo, in vitro, and biochemical virus detection analysis. Our experts can design and develop an appropriate contamination test plan for your biological products, and select available and customized analytical methods that meet your specific needs. We support impurity testing at all stages of the process.
Profacgen addresses the multifaceted challenges of residual impurity control in biologic drug development:
Microbial & Fungal Contamination: The contamination of bacteria and fungi will make the cell experiment unable to continue; therefore, detecting the sterility of cultured cells and final products is essential to maintain valid experimental and manufacturing outcomes
Mycoplasma Contamination: Mycoplasma contamination is not easy to detect, but it will directly affect the state of cells inadvertently, silently compromising product quality and cell-based assay integrity
Endotoxin Toxicity: Endotoxin is a component of the cell wall of Gram-negative bacteria, which is toxic to the host; detection and control are necessary to avoid adverse reactions when recombinant protein is used in animal experiments or administered to patients
Host Cell Protein (HCP) Immunogenicity: HCP in biological products, as a foreign protein, may induce immune response in varying degrees, and eventually lead to allergic reactions or other adverse reactions, necessitating sensitive coverage assessment
Host Cell DNA (HCD) Safety Risk: DNA fragments of host cells may still remain in products after strict purification; the size and composition of these residual DNA fragments are uncertain, and the potential risk is uncertain, which may bring infectious, tumorigenic, or mutagenic risks
Regulatory Complexity: Drug regulatory authorities of various countries have very strict requirements on the limits of DNA impurities, HCP levels, endotoxin, and microbial contaminants, making validated, stage-appropriate testing a critical path activity for IND and BLA submissions
Our Core Platforms
Profacgen deploys a suite of orthogonal analytical platforms to detect and quantify residual impurities across the biopharmaceutical manufacturing lifecycle. Each method is developed, qualified, or validated according to ICH Q2(R1), USP, and EP principles, and tailored to your specific product and process stage.
Platform
Capabilities & Deliverables
Microbiology & Mycoplasma Testing
Bacteria, fungi, and mycoplasma sterility testing for cultured cells, cell banks, and final drug products per USP <63>, USP <71>, and EP 2.6.7
Culture-based and rapid molecular (qPCR/NGS) detection methods for early contamination identification
In-process monitoring to prevent undetected microbial proliferation that would invalidate batches or compromise cell state
Endotoxin Testing
Limulus Amebocyte Lysate (LAL) and recombinant Factor C (rFC) assays per USP <85> and EP 2.6.14 for Gram-negative bacterial endotoxin quantification
Gel-clot, kinetic turbidimetric, and chromogenic LAL methodologies selected based on sample matrix and required sensitivity
Services supporting research, clinical, environmental, and pharmaceutical or medical device industries with mature technology and validated equipment
Host Cell Protein (HCP) Assays
2D DIGE-based HCP antibody coverage assessment: extraction of total host-cell protein, fluorescent labeling of protein and antibody, 2D separation, laser scanning, membrane transfer, antibody incubation, and software-driven coverage analysis
Validation of anti-HCP polyclonal antibody suitability for downstream ELISA and Western blot quantification
Identification and semi-quantification of individual HCP species by 2D-PAGE or LC-MS/MS for process optimization
Host Cell DNA (HCD) / Residual DNA Assays
qPCR-based quantification with high sequence specificity, high sensitivity, good reproducibility, and minimal human interference
Detection of residual DNA fragments from continuous cell lines (CHO, HEK293, E. coli, yeast) in recombinant protein drugs, antibody drugs, and vaccines
Internationally recognized method for process research and product quality control, with regulatory-compliant limit testing per ICH Q5B and WHO TRS 987
Viral Safety & Adventitious Agent Testing
In vivo and in vitro adventitious virus detection assays, including indicator cell culture, transmission electron microscopy (TEM), and biochemical tests (e.g., reverse transcriptase activity)
Molecular methods (qPCR, NGS) for specific and broad-spectrum viral contamination screening
Comprehensive viral clearance strategy documentation for IND, BLA, and MAA filings
Process & Product-Related Impurity Detection
Customized analytical method development for purification residuals, leachables, and product-specific degradants
Orthogonal techniques (RP-HPLC, SEC-HPLC, ion-exchange chromatography, mass spectrometry) tailored to your drug substance and drug product
Integrated quality control from master cell banking through final drug product release, with CTD-formatted documentation
Comprehensive Pharmacopoeial Compliance: All microbiology, endotoxin, mycoplasma, HCP, and HCD assays are performed in accordance with USP, EP, JP, ICH Q5A(R2), Q5D, and WHO guidelines, ensuring global regulatory acceptability.
Advanced HCP Antibody Validation: Our proprietary 2D DIGE workflow provides objective, image-based coverage analysis of anti-HCP antibodies, eliminating the guesswork of traditional Western blot spot-counting and ensuring your ELISA is fit-for-purpose.
Gold-Standard Residual DNA Quantification: qPCR is internationally recognized as the standard method for host residual DNA detection; our assays offer high sequence specificity, high sensitivity, good reproducibility, and less human interference compared to hybridization-based methods.
Integrated Viral Safety: We combine in vivo, in vitro, and biochemical virus detection with modern molecular methods to deliver a complete adventitious agent safety package suitable for cell substrate qualification and product release.
End-to-End Process Support: From cell banking and upstream bioprocess monitoring through downstream clearance validation and final drug product release, our modular service structure scales with your program at every development phase.
Regulatory-Ready Documentation: We deliver method development reports, validation protocols, CoAs, stability data, and CTD-formatted narratives designed for direct inclusion in IND, BLA, and MAA submissions.
A biotech company observed declining cell viability and inconsistent productivity across consecutive bioreactor runs. Standard viability assays showed no clear cause, yet downstream yields were compromised. Undetected microbial or mycoplasma contamination was suspected as the root cause.
Our Solution:
We implemented a comprehensive upstream monitoring panel comprising bacteria, fungi, and mycoplasma sterility testing for culture media, inoculum cells, and bioreactor harvest samples. Mycoplasma detection was performed using both culture-based methods and rapid qPCR to ensure no false negatives. Endotoxin levels in media supplements were also quantified by kinetic turbidimetric LAL.
Final Results:
Profacgen identified low-level mycoplasma contamination in the master cell bank that had evaded routine testing. The client re-derived the cell line from a confirmed clean vial, re-established the working cell bank, and implemented our quarterly mycoplasma monitoring protocol. Subsequent batches showed restored viability and consistent titers, preventing further loss of clinical-grade material.
A vaccine manufacturer needed to demonstrate that its purification process effectively removed host cell proteins (HCPs) and residual DNA from a continuous CHO cell line. During technical review, additional orthogonal evidence beyond standard ELISA and dot-blot methods was requested to support the justification of acceptance criteria for HCP and HCD limits in the late-stage development package.
Our Solution:
For HCP analysis, we performed a 2D DIGE-based antibody coverage assessment. Total CHO proteins were extracted, labeled with Cy3, and separated by two-dimensional electrophoresis to generate a comprehensive protein map. The proteins were then transferred to a membrane and probed with Cy5-labeled anti-CHO antibodies. By comparing fluorescence signals from both scans, software analysis quantified the antibody coverage of HCP species. For HCD, we developed and validated a qPCR method targeting conserved CHO genomic sequences, achieving high specificity, sensitivity down to 1 pg/mL, and strong reproducibility with minimal operator variability.
Final Results:
The 2D DIGE analysis demonstrated that the existing polyclonal antibody covered approximately 85% of detectable HCP species, supporting its suitability for process monitoring. The validated qPCR method consistently quantified residual DNA levels below commonly accepted safety thresholds. Together, these orthogonal datasets provided robust evidence of impurity clearance, supporting process validation and enabling uninterrupted progression into large-scale manufacturing.
Q: What are process-related residual impurities and why must they be controlled in biological products?
A: Process-related residual impurities include microbial contaminants, mycoplasma, endotoxins, host cell proteins (HCP), host cell DNA (HCD), and adventitious agents introduced during manufacturing. These impurities must be controlled because they can compromise cell viability, induce immunogenicity, or pose infectious, tumorigenic, or mutagenic risks to patients. Regulatory authorities mandate strict limits to ensure drug safety and support registration.
Q: Which regulatory guidelines govern residual impurity testing for biopharmaceuticals?
A: Key guidelines include ICH Q5A(R2) (viral safety), ICH Q5D (cell substrates), USP <63> (mycoplasma tests), USP <85> (bacterial endotoxins), USP <71> (sterility), and WHO TRS 987 (residual DNA). Regional agencies—FDA, EMA, and NMPA—enforce these standards through IND, BLA, and MAA review processes.
Q: How does Profacgen detect mycoplasma contamination in cell cultures?
A: We employ both culture-based methods and rapid molecular detection (qPCR). Mycoplasma contamination is not easy to detect by routine microscopy, yet it directly affects cell state inadvertently. Our dual-approach testing ensures high sensitivity and specificity, preventing false negatives that could compromise entire batch lines or invalidate experimental data.
Q: What is the difference between HCP and HCD assays, and why are both necessary?
A: HCP (Host Cell Protein) assays detect residual protein impurities from the expression system; as foreign proteins, HCPs may induce immune responses and lead to allergic or adverse reactions. HCD (Host Cell DNA) assays quantify residual DNA fragments that may carry infectious, tumorigenic, or mutagenic risks. Both are required because proteins and DNA represent distinct safety hazards with different clearance mechanisms and regulatory limits.
Q: Why does Profacgen use 2D DIGE for HCP antibody coverage assessment?
A: 2D DIGE (two-dimensional difference gel electrophoresis) enables objective, fluorescence-based comparison of total host-cell proteins versus antibody-bound proteins on the same gel. We extract total host protein, label it with one fluorophore and the anti-HCP antibody with another, perform 2D separation, and scan both channels. Software analysis determines the exact coverage percentage, ensuring the antibody is sufficiently broad and specific for downstream ELISA or Western blot validation.
Q: Why is qPCR the preferred method for residual DNA quantification?
A: qPCR has the advantages of high sequence specificity, high sensitivity, good reproducibility, and less human interference compared to traditional DNA hybridization assays. It can reliably detect residual DNA fragments from continuous cell lines at picogram-per-milliliter levels, making it the internationally recognized standard for biopharmaceutical process research and product quality control.
Q: At which manufacturing stages can Profacgen support residual impurity testing?
A: We support impurity testing at all stages of the process, including master and working cell bank characterization, upstream cell culture monitoring, downstream purification clearance validation, bulk drug substance release, and final drug product lot release. Our experts design appropriate contamination test plans and select customized analytical methods that meet your specific needs at every phase.
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
